Want to see BHVN full AI Analyst Report?
BHVN Stock Chart & Stats
$14.32
-$0.33(-2.25%)
At close: 4:00 PM EDT
$14.32
-$0.33(-2.25%)
Day’s Range― - ―
52-Week Range$7.48 - $18.57
Previous CloseN/A
Volume1.72M
Average Volume (3M)3.16M
Market Cap
$2.03B
Enterprise Value$1.19K
Total Cash (Recent Filing)$347.82M
Total Debt (Recent Filing)$286.18M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 03, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.67
Shares Outstanding150,560,990
10 Day Avg. Volume1,832,109
30 Day Avg. Volume3,164,803
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.70Price Target Upside23.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Opakalim Clinical DataRobust proof-of-concept results and a differentiated efficacy-tolerability profile increase the probability of successful pivotal readouts in H2 2026. Positive Phase 2/3 outcomes would validate the CNS pipeline, support regulatory/partnering paths, and materially improve the company's ability to generate durable clinical and commercial value.
Strengthened Discovery LeadershipElevating a dedicated Head of Discovery and formalizing the CSO's innovation role signals a structural focus on internal R&D and external collaborations. Improved discovery governance and execution capability can accelerate early-stage programs, increase dealflow quality with partners, and sustain long-term pipeline renewal independent of single assets.
Governance And Shareholder SupportClear shareholder backing for the board, auditor, and pay program provides governance continuity that reduces the chance of disruptive activist interventions. Stable oversight supports consistent strategy execution, smoother capital-raising discussions, and sustained relationships with partners and investors over the medium term.
Bears Say
Zero Revenue; Large Persistent LossesThe company remains pre-revenue with substantial recurring losses, meaning value depends entirely on clinical progress and financing. Persistent losses erode equity and limit reinvestment capacity, making execution risk and milestone delivery the primary drivers of long-term viability absent near-term commercialization.
Deep Negative Cash FlowSustained, large negative operating and free cash flows create ongoing funding needs and shrink strategic flexibility. Continued burn increases reliance on external capital or partnerships, compresses runway, and forces trade-offs in program prioritization that can slow development and dilute long-term shareholder value.
Deteriorated Balance Sheet And Higher LeverageA sharp increase in leverage and compressed equity reduce financial resilience and raise refinancing risk. Higher debt levels can constrain strategic actions, increase interest burden, and limit the company's ability to absorb setbacks in clinical development without expensive or dilutive financing alternatives.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $18.57 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $2.03B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Aug 03, 2026 which is today.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on May 04, 2026. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.831 by -$0.049.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.76.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 150,560,990 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.831. Following the earnings report the stock price went down -4.241%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.70 (23.60% Upside)
$17.70 (23.60% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 757.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.63%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
BHVN Stock 12 Month Forecast
Average Price Target
$17.70
▲(23.60% Upside)
Technical Analysis
Ownership Overview
10.77% Insiders
11.98% Mutual Funds
2.60% Other Institutional Investors
66.24% Public Companies and
Individual Investors